Cited by 596Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

Lei, Peng, Ayton, Scott, Finkelstein, David I, Spoerri, Loredana, Ciccotosto, Giuseppe D, Wright, David K, Wong, Bruce X W, Adlard, Paul A +9 more·2012·Nature Medicine

Abstract

The microtubule-associated protein tau has risk alleles for both Alzheimer's disease and Parkinson's disease and mutations that cause brain degenerative diseases termed tauopathies. Aggregated tau forms neurofibrillary tangles in these pathologies, but little is certain about the function of tau or its mode of involvement in pathogenesis. Neuronal iron accumulation has been observed pathologically in the cortex in Alzheimer's disease, the substantia nigra (SN) in Parkinson's disease and various brain regions in the tauopathies. Here we report that tau-knockout mice develop age-dependent brain atrophy, iron accumulation and SN neuronal loss, with concomitant cognitive deficits and parkinsonism. These changes are prevented by oral treatment with a moderate iron chelator, clioquinol. Amyloid precursor protein (APP) ferroxidase activity couples with surface ferroportin to export iron, but its activity is inhibited in Alzheimer's disease, thereby causing neuronal iron accumulation. In primary neuronal culture, we found loss of tau also causes iron retention, by decreasing surface trafficking of APP. Soluble tau levels fall in affected brain regions in Alzheimer's disease and tauopathies, and we found a similar decrease of soluble tau in the SN in both Parkinson's disease and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model. These data suggest that the loss of soluble tau could contribute to toxic neuronal iron accumulation in Alzheimer's disease, Parkinson's disease and tauopathies, and that it can be rescued pharmacologically.

Integrity signals

Registry

Crossref · 10.1038/nm.2613

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau-mediated neurodegeneration arises from multiple pathological mechanisms including loss of normal function, gain of toxic function, aggregation, and mislocalization.

    “Tau-mediated neurodegeneration arises from multiple pathological mechanisms, including loss of normal function [37–42], gain of toxic function [43–46], aggregation [44, 47–49], and mislocalization [50–52].”
  • Additional physiological functions for tau include regulation of iron export and insulin signaling.

    “Additional physiological functions for tau include regulation of iron export and insulin signaling [139, 140].”
  • Tau deficiency impairs ferroportin iron export by retaining APP in the endoplasmic reticulum so that it can no longer be trafficked to the neuronal surface, where it can couple its ferroxidase activity to ferroportin.

    “Tau deficiency impairs ferroportin iron export by retaining APP in the endoplasmic reticulum so that it can no longer be trafficked to the neuronal surface, where it can couple its ferroxidase activity to ferroportin.”
  • MAPT deficiency induces intracellular iron accumulation, which causes degeneration of dopaminergic neurons, leading to parkinsonism with dementia in mice.

    “Microtubule-associated protein tau (MAPT) deficiency induces intracellular iron accumulation, which causes degeneration of dopaminergic neurons, leading to parkinsonism with dementia in mice.85”
  • In mice, genetic ablation of endogenous tau is well tolerated, with a minor motor phenotype developing only after 12-16 months.

    “In mice, genetic ablation of endogenous tau is well tolerated with a minor motor phenotype developing only after 12–16 months (12–14).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., Roberts, B. R., Volitakis, I., Egan, G. F., McLean, C. A., Cappai, R., Duce, J. A., & Bush, A. I.
Affiliations
  • Mental Health Research Institute (AU)
  • The University of Melbourne (AU)
Corresponding author
Bush, Ashley I
Venue
Nature Medicine
Published
2012-01-29
Volume
18
Issue
2
Pages
291-295
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2039314393
Cited by
594
References
33
Citations by year
2026: 28 · 2025: 25 · 2024: 50 · 2023: 47 · 2022: 49 · 2021: 54 · 2020: 36 · 2019: 47 · 2018: 38 · 2017: 45 · 2016: 38 · 2015: 37 · 2014: 39 · 2013: 39 · 2012: 21
FWCI
29.38
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
tauopathy, Parkinson's disease, Alzheimer's disease, parkinsonism, amyloid precursor protein, ferroportin, iron export, clioquinol, iron chelation, substantia nigra, neurofibrillary tangles, MPTP mouse model, brain atrophy, cognitive impairment, soluble tau
MeSH terms
Age Factors, Aged, Animals, Brain, Brain Chemistry, Ceruloplasmin, Dementia, Humans, Iron, Male, Amyloid beta-Protein Precursor, tau Proteins, Mice, Knockout, Parkinsonian Disorders, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review